Tacrolimus is one of the mainstay medications for renal transplantation patients. Vision loss is a rare but serious adverse effect associated with tacrolimus use. Herein, we report a male patient who developed acute vision loss during hospitalization for slow kidney graft function post-renal transplantation and 19 days after starting tacrolimus. The vision loss was associated with a recent rise in tacrolimus levels that required dose adjustment. The workup excluded cortical blindness and showed evidence of a newly developed bilateral central white cloudy inner retinal opacification resembling a cherry red spot on fundus examination. Tacrolimus toxicity was suspected, and the medication was replaced with cyclosporin. Follow-up was remarkable for mild improvement in the patient's vision and disappearance of structural changes on fundoscopy in both eyes. These findings are in keeping with a diagnosis of ischemic maculopathy. This is the first case of bilateral severe early-onset tacrolimus-associated ischemic maculopathy. According to our workup, this disease can be explained by a vasoocclusive accident at the arteriolar and venular level of the ciliomacular vascular system.
No takes yet. Share an insight, caveat, or question.
Almdallaleh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: